Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Neosoma, a Medical Technology Company Focused on Advancing the Treatment of Brain Cancers

Neosoma, an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its first AI-based neuro-oncology software device, Neosoma HGG (High-Grade Glioma).

Read More About AI News : Role of AI in Helping B2B companies that are Missing Out on Buyer Intent Data

“Neosoma HGG will give us a novel tool allowing for comprehensive longitudinal monitoring and understanding of brain tumors, assist in our decision making, and will be a valuable part of our clinical practice. I look forward to using this new and important technology”

High-Grade Gliomas, which includes Glioblastoma, are the most common, and most challenging, malignant primary brain cancers. In clinical practice, the brain MRI is the physician’s best tool to evaluate the details and changes in a brain tumor. However, even for the most experienced physicians this presents considerable challenges, which can have a direct impact on clinical care.

Neosoma HGG is the first technology of its kind to support neuro-oncology clinicians in improving treatment. Using advanced AI-based technology, Neosoma HGG produces precise and accurate brain tumor analysis on brain MRIs, providing physicians with critical insights to help them deliver optimal treatment.

Neosoma HGG conducts detailed tumor segmentation, volumetric measurements, generates imaging for 3D geometric analysis and longitudinally tracks patients with high-grade glioma brain tumors. These features will help physicians to better plan procedures, assess post-procedural results, guide chemo and immunotherapy treatments and support an improved patient experience.

Related Posts
1 of 32,253

Browse The Complete News About AI : Anari AI Launches Thor X to Enhance Cloud-based 3D Applications

“Clinicians commonly debate the results of brain MRIs and whether the brain tumor is stable, responding to treatment, or progressing. Neosoma HGG will give us the objectivity needed to make our decisions easier and more accurate,” commented Isabelle M. Germano, MD, MBA, FACS, Professor of Neurosurgery and Director of the Comprehensive Brain Tumor Program at The Mount Sinai Medical Center.

Performance testing results, submitted to the FDA, demonstrated that Neosoma HGG’s outputs exceeded that of individual neuro-radiology experts. When compared to a consensus of neuroradiologists, Neosoma HGG achieved an excellent 95.5% accuracy in measuring tumor volumes at multiple timepoints of patient care.

Neosoma HGG is combined with the proprietary Neosoma Clinical Management Software Platform, allowing the multi-disciplinary physician team more effectively centralize clinical data, plan and track patient care, and significantly increase efficiency.

“Neosoma HGG will give us a novel tool allowing for comprehensive longitudinal monitoring and understanding of brain tumors, assist in our decision making, and will be a valuable part of our clinical practice. I look forward to using this new and important technology,” stated Roger Stupp, M.D., Chief of Neuro-oncology and Co-director of the Northwestern Medicine Malnati Brain Tumor Institute and Professor of Neurological Surgery, Neurology and Medicine at Northwestern University in Chicago, IL.

Future of AI-driven Customer Relationship:  Microsoft’s Viva Sales and the Future of AI-driven Customer Relationship and Experience Management

[To share your insights with us, please write to sghosh@martechseries.com] 

Comments are closed.